Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 20:31 | 2026-05-07 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $586.75 | 8,300 | $4,870,054 | 45,172 |
| 2026-05-07 20:15 | 2026-05-06 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $153.84 | 1,000 | $153,839 | 666 |
| 2026-05-07 20:15 | 2026-05-06 | AVTX | Avalo Therapeutics, Inc. | Chan Mitchell | Director | SELL | $22.88 | 3,167 | $72,461 | 3,166 |
| 2026-05-07 20:16 | 2026-05-05 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer | OPT+S | $20.61 | 108,234 | $2,230,367 | 3,622 |
| 2026-05-07 20:16 | 2026-05-06 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Officer | OPT+S | $20.19 | 47,000 | $948,723 | 423 |
| 2026-05-07 20:18 | 2026-05-06 | AVTX | Avalo Therapeutics, Inc. | VARKI PAUL | Officer | OPT+S | $20.17 | 75,063 | $1,513,675 | 3,634 |
| 2026-05-07 20:00 | 2026-05-06 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | SELL | $995.36 | 15,828 | $15,754,536 | 91,881,150 | |
| 2026-05-07 20:00 | 2026-05-06 | OGN | Organon & Co. | Holzbaur Lynette | Officer | SELL | $13.35 | 26,448 | $353,080 | 0 |
| 2026-05-07 20:01 | 2026-05-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | Officer | SELL | $35.40 | 30,000 | $1,062,000 | 55,755 |
| 2026-05-07 20:02 | 2026-05-05 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | Officer | SELL | $54.99 | 1,207 | $66,373 | 42,820 |
| 2026-05-07 20:03 | 2026-05-06 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Weiss Amir | Officer | SELL | $36.00 | 10,679 | $384,444 | 20,016 |
| 2026-05-07 14:02 | 2026-05-06 | OGN | Organon & Co. | Holzbaur Lynette | Officer | BUY | $13.35 | 26,448 | $353,080 | 52,851 |
| 2026-05-06 20:11 | 2026-05-04 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $137.34 | 10,699 | $1,469,441 | 301,185 |
| 2026-05-07 01:53 | 2026-05-04 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | Officer | SELL | $2.51 | 25,240 | $63,352 | 986,851 |
| 2026-05-07 01:32 | 2026-04-28 | TLX | Telix Pharmaceuticals Ltd | Behrenbruch Christian | Director, Officer | BUY | $14.67 | 67,935 | $996,736 | 20,742,935 |
| 2026-05-07 01:32 | 2026-05-04 | RLYB | Rallybio Corp | ADAR1 Capital Management, LLC | 10% owner | BUY | $13.97 | 155,905 | $2,178,663 | 779,784 |
| 2026-05-07 00:15 | 2026-05-04 | MPLT | MapLight Therapeutics, Inc. | Kroeger Christopher A. | Director, Officer | SELL | $28.39 | 49,744 | $1,412,237 | 1,580,820 |
| 2026-05-07 00:15 | 2026-05-04 | MPLT | MapLight Therapeutics, Inc. | Hanson Kristopher | Officer | SELL | $27.89 | 13,917 | $388,177 | 176,248 |
| 2026-05-07 00:15 | 2026-05-04 | MPLT | MapLight Therapeutics, Inc. | Lillie James Woodruff | Officer | SELL | $28.40 | 51,707 | $1,468,251 | 243,450 |
| 2026-05-07 00:15 | 2026-05-04 | MPLT | MapLight Therapeutics, Inc. | Foff Erin Pennock | Officer | SELL | $28.39 | 50,280 | $1,427,595 | 350,497 |
| 2026-05-07 00:15 | 2026-05-04 | MPLT | MapLight Therapeutics, Inc. | Setia Vishwas | Officer | SELL | $28.17 | 36,371 | $1,024,720 | 356,256 |
| 2026-05-07 00:00 | 2026-05-05 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | Officer | OPT+S | $46.31 | 2,491 | $115,368 | 118,658 |
| 2026-05-07 00:00 | 2026-05-06 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer | OPT+S | $43.95 | 22,500 | $988,875 | 432,886 |
| 2026-05-07 00:00 | 2026-05-05 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Officer | OPT+S | $46.65 | 2,174 | $101,417 | 140,684 |
| 2026-05-07 00:00 | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Officer | OPT+S | $45.15 | 22,485 | $1,015,085 | 113,238 |
| 2026-05-07 00:00 | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer | OPT+S | $45.06 | 24,250 | $1,092,657 | 105,211 |
| 2026-05-07 00:00 | 2026-05-06 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Officer | OPT+S | $43.95 | 2,763 | $121,434 | 115,474 |
| 2026-05-07 00:00 | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Director | OPT+S | $45.00 | 8,000 | $360,000 | 87,500 |
| 2026-05-07 00:00 | 2026-05-05 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Director | OPT+S | $46.65 | 4,500 | $209,925 | 37,500 |
| 2026-05-06 23:40 | 2026-05-04 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | Officer | SELL | $23.31 | 8,256 | $192,415 | 126,689 |
| 2026-05-06 22:06 | 2026-05-04 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | Director, Officer | SELL | $23.61 | 3,172 | $74,893 | 720,755 |
| 2026-05-06 22:13 | 2026-05-04 | ARQT | Arcutis Biotherapeutics, Inc. | Vairavan Latha | Officer | SELL | $23.61 | 1,341 | $31,662 | 86,413 |
| 2026-05-06 22:15 | 2026-05-04 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | Officer | SELL | $23.61 | 684 | $16,150 | 120,466 |
| 2026-05-06 21:27 | 2026-05-04 | IONS | IONIS PHARMACEUTICALS INC | LOSCALZO JOSEPH | Director | OPT+S | $75.06 | 77,289 | $5,801,227 | 36,330 |
| 2026-05-06 21:04 | 2026-05-05 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $576.24 | 9,500 | $5,474,240 | 40,513 |
| 2026-05-06 21:09 | 2026-05-04 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Director | SELL | $18.14 | 106,723 | $1,936,339 | 1,136,810 |
| 2026-05-06 21:16 | 2026-05-05 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | Officer | SELL | $55.32 | 346 | $19,141 | 44,334 |
| 2026-05-06 20:30 | 2026-05-04 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $101.69 | 30,000 | $3,050,712 | 324,879 |
| 2026-05-06 20:15 | 2026-05-05 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $155.50 | 1,000 | $155,503 | 1,666 |
| 2026-05-06 20:01 | 2026-05-04 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $5.82 | 806 | $4,691 | 612,113 |
| 2026-05-06 18:51 | 2026-05-05 | RARE | Ultragenyx Pharmaceutical Inc. | Crombez Eric | Officer | SELL | $24.96 | 344 | $8,586 | 111,189 |
| 2026-05-05 20:15 | 2026-05-04 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $155.64 | 1,000 | $155,636 | 2,666 |
| 2026-05-05 20:54 | 2026-05-01 | KNSA | Kiniksa Pharmaceuticals International, plc | Paolini John F. | Officer | OPT+S | $53.71 | 58,424 | $3,137,825 | 65,623 |
| 2026-05-05 20:51 | 2026-05-04 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bhatia Sangeeta N. | Director | SELL | $423.73 | 318 | $134,746 | 4,924 |
| 2026-05-05 20:15 | 2026-05-01 | AVLN | Avalyn Pharma Inc. | Novo Holdings A/S | 10% owner | BUY | $18.00 | 555,555 | $9,999,990 | 3,883,289 |
| 2026-05-05 20:27 | 2026-05-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | SELL | $203.33 | 6,000 | $1,219,980 | 378,682 |
| 2026-05-05 21:35 | 2026-05-05 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $77.37 | 3,500 | $270,795 | 153,902 |
| 2026-05-05 20:20 | 2026-05-05 | CYTK | CYTOKINETICS INC | WIERENGA WENDELL | Director | OPT+S | $75.00 | 4,032 | $302,400 | 32,637 |
| 2026-05-05 20:15 | 2026-05-05 | CYTK | CYTOKINETICS INC | HENDERSON JOHN T | Director | OPT+S | $75.97 | 20,000 | $1,519,400 | 75,237 |
| 2026-05-05 20:11 | 2026-05-05 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $77.25 | 11,333 | $875,474 | 58,555 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.